Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aliskiren · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Aliskiren 600 mg |
| 2 | ACTIVE_COMPARATOR | Aliskiren 150 mg |
| 3 | ACTIVE_COMPARATOR | Losartan 100 mg |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Aliskiren | DRUG | Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period. |
| Comparator: Losartan | DRUG | Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period. |
| Comparator: Placebo to Aliskiren | DRUG | Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period. |
| Comparator: Placebo to Losartan | DRUG | Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period. |
Inclusion Criteria: * Subject is in generally good health * Subject is willing to avoid unaccustomed strenuous exercise during the study * Subject agrees to consume ONLY the study-specified diet during all domiciled periods * Subject has been a non-smoker for at least 3 months prior to study * Subj...
Aliskiren is a small molecule drug being developed for the treatment of hypertension, a condition of high blood pressure. It is currently in Phase 1 clinical development as an investigational therapy. The drug is being studied for its effects on renal blood flow in healthy male volunteers.
Aliskiren is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and effects in healthy volunteers with hypertension.
Aliskiren is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and pharmacological effects. The drug is being studied in a small, early-stage trial.
Aliskiren has one completed clinical trial registered under NCT00856960, titled "The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)." This Phase 1 study enrolled 12 healthy male participants and was a randomized, double-blind, placebo-controlled trial.
Aliskiren is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for hypertension. The drug has completed one early-stage trial, but it has not received regulatory approval and remains under investigation for its safety and efficacy.